Dose subjects but not using them [Two-Stage / GS Designs]

posted by d_labes  – Berlin, Germany, 2015-09-22 15:49 (3135 d 17:30 ago) – Posting: # 15445
Views: 4,628

Dear Kotu,

sounds to me in contrast to our Capt'n like something similar to 'spare' subjects.

The EMA guidance states in this respect:
"The data from all treated subjects should be treated equally. It is not acceptable to have a protocol which specifies that ‘spare’ subjects will be included in the analysis only if needed as replacements for other subjects who have been excluded. It should be planned that all treated subjects should be included in the analysis, even if there are no drop-outs."

Moreover it is IMHO highly unethical to expose subjects to the API and taking blood samples from them for nothing (not to use their data).

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
22,990 posts in 4,826 threads, 1,665 registered users;
62 visitors (0 registered, 62 guests [including 6 identified bots]).
Forum time: 09:19 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5